InMed Pharmaceuticals (INM) Institutional Ownership $2.75 -0.07 (-2.48%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.73 -0.02 (-0.73%) As of 07/11/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for InMed Pharmaceuticals (NASDAQ:INM)CurrentInstitutional OwnershipPercentage20.12%Number ofInstitutional Buyers(last 12 months)0Number ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$3.29M Get INM Insider Trade Alerts Want to know when executives and insiders are buying or selling InMed Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data INM Institutional Buying and Selling by Quarter InMed Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025AdvisorShares Investments LLC38,460$177K0.0%-94.8%5.342% 2/13/2024Armistice Capital LLC205,968$86K0.0%N/A3.916% 11/14/2022Armistice Capital LLC90,000$593K0.0%-90.6%9.605% 5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437% 8/17/2021Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954% 8/12/2021Penserra Capital Management LLC19,912$49K0.0%N/A0.223% 5/21/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214% 5/18/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214% 5/17/2021Armistice Capital LLC235,000$776K0.0%N/A2.919% (Data available from 1/1/2016 forward) INM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of INM shares? During the previous two years, the following institutional investors and hedge funds held shares of InMed Pharmaceuticals shares: AdvisorShares Investments LLC ($177K), Armistice Capital LLC ($86K).Learn more on InMed Pharmaceuticals' institutional investors. What percentage of InMed Pharmaceuticals' stock is owned by institutional investors? 20.12% of InMed Pharmaceuticals' stock is owned by institutional investors. Learn more on INM's institutional investor holdings. Which institutional investors have been buying InMed Pharmaceuticals' stock? The following institutional investors have purchased InMed Pharmaceuticals' stock in the last 24 months: Armistice Capital LLC ($205.97K). Which of InMed Pharmaceuticals' major shareholders have been selling company stock? The following institutional investors have sold InMed Pharmaceuticals stock in the last 24 months: AdvisorShares Investments LLC ($694.84K). How much institutional selling is happening at InMed Pharmaceuticals? Institutional investors have sold a total of 694,836 shares in the last 24 months. This volume of shares sold represents approximately $3.29M in transactions. Related Companies IMNN Major Shareholders RLYB Major Shareholders SYBX Major Shareholders TXMD Major Shareholders TRIB Major Shareholders NKGN Major Shareholders FLGC Major Shareholders NEUP Major Shareholders ME Major Shareholders ATHA Major Shareholders This page (NASDAQ:INM) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
